IPOs
Filter News
Found 16,992 articles
-
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
1/3/2024
Entera Bio Ltd. announced that, on December 27, 2023, it received an extension of 180 calendar days from the Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
-
XOMA Announces Stock Repurchase Program of up to $50 Million
1/2/2024
XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA’s first stock repurchase program, which permits the Company to purchase up to $50 million of XOMA’s common stock through January 2027.
-
NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard
1/2/2024
NRx Pharmaceuticals, Inc. today announced an update on plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed Securities (MVLS).
-
TC BioPharm Announces Closing of $3.5 Million Public Offering
12/22/2023
TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.
-
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
12/22/2023
Cyclacel Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock.
-
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
12/22/2023
Elicio Therapeutics, Inc. announced today that it has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC.
-
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/21/2023
Longeveron Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.
-
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
12/21/2023
Panbela Therapeutics, Inc. today announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,556,000 shares of its common stock.
-
Pharma-Bio Serv Announces Special Dividend - December 21, 2023
12/21/2023
Pharma-Bio Serv, Inc. today announced that the Board of Directors approved a Special Dividend of $0.075 per share for Shareholders.
-
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 20, 2023
12/20/2023
Castle Biosciences, Inc. today announced that on Dec. 18, 2023, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 52 employees covering an aggregate of 170,913 shares of common stock as an inducement material to their entering into employment with Castle Biosciences.
-
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
12/19/2023
Biodexa Pharmaceuticals PLC, today announced the pricing of an underwritten public offering of units.
-
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
12/19/2023
NeuroBo Pharmaceuticals, Inc. today announced a 1-for-8 reverse stock split of the Company's Common Stock, par value $0.001.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 19, 2023
12/19/2023
Schrödinger, Inc. today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees.
-
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements - December 19, 2023
12/19/2023
On November 21, 2023, FOXO Technologies Inc., a Delaware corporation (the “ Company ”), received an official notice of noncompliance.
-
TC BioPharm Announces Pricing of $3.5 Million Public Offering
12/19/2023
TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.
-
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
12/19/2023
Syros Pharmaceuticals announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 18, 2023
12/18/2023
EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
-
Tourmaline Bio added to the NASDAQ Biotechnology Index - December 15, 2023
12/15/2023
Tourmaline Bio, Inc. announced that Tourmaline has been added to the NASDAQ Biotechnology Index, effective prior to market open, Monday, December 18, 2023.
-
Astiva Health Files Statement for Proposed Initial Public Offering
12/15/2023
Astiva Health Inc., a fast-growing Medicare Advantage Prescription Drug (MAPD) health plan dedicated to reshaping personalized and comprehensive healthcare, announced today that it has started the process of registering its common shares on the Nasdaq Global Select.
-
What VCs really think of the market right now with MPM Capital, Endeavor and Two Bear Capital
12/14/2023
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen.